-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Sage Therapeutics, editor of WuXi AppTec's content team, recently announced its potential "first-in-class" NMDA receptor allosteric modulator SAGE-718 for the treatment of mild cognitive impairment (MCI) and Alzheimer's disease (AD) Results of a phase 2 clinical trial in patients with mild dementia
.
The data showed that SAGE-718 was well tolerated and was associated with improvements in several tests of executive ability and learning and memory
.
In the study, 26 patients were treated with SAGE-718 for 14 days and a comprehensive panel of tests was used to assess multiple domains of their cognitive abilities
.
On day 14, improvements from baseline were observed in multiple tests examining executive ability (numerical symbol substitution, multitasking, spatial working memory, etc.
) and learning memory (pattern recognition memory and speech recognition memory)
.
A statistically significant improvement in the Montreal Cognitive Assessment Scale (MoCA) was observed on day 28 (increase of 2.
3 points from baseline)
.
Functional assessment also found improvements in some patients on the Clinical Global Impression Scale and the Amsterdam Instrumental Activities of Daily Living Questionnaire, particularly items that measure complex/higher-order activities
.
Image credit: 123RFSAGE-718 was generally well tolerated in this study
.
Eight mild/moderate treatment-emergent adverse events (TEAEs) were reported in seven patients
.
No serious adverse events or deaths were reported
.
"Alzheimer's is one of the disease areas with the greatest unmet patient need, with an estimated number of more than 134 million people worldwide, with few treatment options specifically for mild cognitive impairment and mild dementia
.
"We are encouraged by the positive results of this study, which are consistent with the signals of cognitive improvement observed in other SAGE-718 development programs, including Parkinson's disease and Huntington's," said Dr.
Jim Doherty, Chief Development Officer, Sage.
sick patients
.
We look forward to learning more about the potential of SAGE-718
.
"Reference: [1] Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY Study of SAGE-718 in Patients with Mild Cognitive Impairment and Mild Dementia due to Alzheimer's Disease.
Retrieved April 1, 2022, from https://www .
businesswire.
com/news/home/20220331006048/enDisclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the views in this article do not represent WuXi AppTec's position, nor do they represent pharmaceutical Mingkant supports or opposes the views in the article
.
This article is not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital for treatment
.
.
The data showed that SAGE-718 was well tolerated and was associated with improvements in several tests of executive ability and learning and memory
.
In the study, 26 patients were treated with SAGE-718 for 14 days and a comprehensive panel of tests was used to assess multiple domains of their cognitive abilities
.
On day 14, improvements from baseline were observed in multiple tests examining executive ability (numerical symbol substitution, multitasking, spatial working memory, etc.
) and learning memory (pattern recognition memory and speech recognition memory)
.
A statistically significant improvement in the Montreal Cognitive Assessment Scale (MoCA) was observed on day 28 (increase of 2.
3 points from baseline)
.
Functional assessment also found improvements in some patients on the Clinical Global Impression Scale and the Amsterdam Instrumental Activities of Daily Living Questionnaire, particularly items that measure complex/higher-order activities
.
Image credit: 123RFSAGE-718 was generally well tolerated in this study
.
Eight mild/moderate treatment-emergent adverse events (TEAEs) were reported in seven patients
.
No serious adverse events or deaths were reported
.
"Alzheimer's is one of the disease areas with the greatest unmet patient need, with an estimated number of more than 134 million people worldwide, with few treatment options specifically for mild cognitive impairment and mild dementia
.
"We are encouraged by the positive results of this study, which are consistent with the signals of cognitive improvement observed in other SAGE-718 development programs, including Parkinson's disease and Huntington's," said Dr.
Jim Doherty, Chief Development Officer, Sage.
sick patients
.
We look forward to learning more about the potential of SAGE-718
.
"Reference: [1] Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY Study of SAGE-718 in Patients with Mild Cognitive Impairment and Mild Dementia due to Alzheimer's Disease.
Retrieved April 1, 2022, from https://www .
businesswire.
com/news/home/20220331006048/enDisclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the views in this article do not represent WuXi AppTec's position, nor do they represent pharmaceutical Mingkant supports or opposes the views in the article
.
This article is not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital for treatment
.
